2+ day, 18+ hour ago   (408+ words) A survey of 175 pharma executives highlights an increasing reluctance to launch in lower-value markets, alongside a heightened focus on RWE. A new report from business management consultancy, Numerof & Associates has found that pharma executives are increasingly rethinking the launch of…...

1+ week, 4+ day ago   (487+ words) In Association with Thermo Fisher Scientific As licensing expands, manufacturing evidence is becoming a decisive test of asset value and deal confidence. This is increasingly important as pharmaceutical companies look outside their own laboratories for pipeline growth, and chemistry, manufacturing,…...

2+ week, 3+ day ago   (324+ words) The study’s next steps are data review, database lock, statistical analysis, and a clinical study report in 2027. Senhwa Biosciences has completed enrolment in its Phase Ib expansion trial of pidnarulex (CX-5461) as a monotherapy for people with advanced solid tumours…...

2+ week, 3+ day ago   (343+ words) Airway Therapeutics expects to complete an interim analysis of the Phase IIb trial by the end of Q2 2027. Airway Therapeutics has raised $50m in new equity financing to support its ongoing Phase IIb/III clinical trial of zelpultide alfa for the prevention…...

2+ week, 4+ day ago   (473+ words) REGENXBIO has reported that the US Food and Drug Administration (FDA) has placed a clinical hold on its investigational gene therapy, RGX-121 (clemidsogene lanparvovec), developed for the treatment of mucopolysaccharidosis type II (MPS II). Also known as Hunter syndrome, MPS II…...

2+ week, 5+ day ago   (329+ words) The primary goal of the ReVeRA-301 study is to achieve a reduction in ventricular rate within 30 minutes. Milestone Pharmaceuticals has commenced a pivotal Phase III trial of its etripamil nasal spray aimed at treating atrial fibrillation with rapid ventricular rate…...

3+ week, 2+ day ago   (237+ words) Analysts tout this early data as “encouraging” as anti-inflammatory mechanisms garner increasing attention in the neurology and metabolic disease spaces. AC Immune’s anti-inflammatory therapy has netted a Phase I, first-in-human win in healthy volunteers, setting a positive precedent as the…...

4+ week, 1+ day ago   (301+ words) MSD and SCRI aim to address complex oncology studies requiring precise patient selection and faster therapies access. Sarah Cannon Research Institute (SCRI) and Merck & Co (MSD) have entered a collaboration aimed at increasing patient access to oncology clinical trials at…...

1+ mon, 12+ hour ago   (533+ words) Belenos and Keymed will now look to initiate Phase III studies for their co-developed drug in Dupixent-dominated CRSwNP. Belenos Biosciences’ bet worth up to $185m on Keymed Biosciences’ subcutaneous chronic rhinosinusitis with nasal polyps (CRSwNP) therapy is showing early signs of…...

1+ mon, 1+ day ago   (497+ words) If divesiran reaches the PV market, it could become the first siRNA therapy for the indication currently dominated by Jakafi and Besremi. British biotech Silence Therapeutics has been making noise on the stock markets by posting 30% growth in its share…...